Last Updated: November 16, 2026

Claims for Patent: 12,653,789

« Back to Dashboard


Summary for Patent: 12,653,789
Title:Adagrasib solid pharmaceutical compositions
Abstract:Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.
Inventor(s):Cletus NUNES, Mehrdad KHEIRIPOUR, Monika GAVIREDDI
Assignee: Mirati Therapeutics Inc
Application Number:US18/784,276
Patent Claims: 1. A tablet formulation for oral administration in a human, comprising: (1) adagrasib constituting about 30-35% of the tablet formulation; (2) microcrystalline cellulose constituting about 50-55% of the tablet formulation; (3) mannitol constituting about 8-10% of the tablet formulation; (4) crospovidone constituting about 2% to about 5% of the tablet formulation; (5) colloidal silicon dioxide constituting up to about 0.5-1.5% of the tablet formulation; and (6) the magnesium stearate constitutes about 1-2% of the tablet formulation, and wherein all percentages are percentages by weight, and wherein an adverse gastrointestinal event occurs in a lower frequency in the human administered the tablet formulation compared to a human administered a capsule formulation with the same amount of adagrasib.

2. The tablet formulation of claim 1, wherein the tablet formulation further comprises a film coat.

3. The tablet formulation of claim 1, wherein: (1) the adagrasib constitutes about 33.3% of the tablet formulation; (2) the microcrystalline cellulose constitutes about 51.2% of the tablet formulation; (3) the mannitol constitutes about 10.0% of the tablet formulation; (4) the crospovidone constitutes about 3.0% of the tablet formulation; (5) the colloidal silicon dioxide constitutes about 1.0% of the tablet formulation; and (6) the magnesium stearate constitutes about 1.5% of the tablet formulation.

4. The tablet formulation of claim 1, wherein the adverse gastrointestinal event is nausea.

5. The tablet formulation of claim 1, wherein the adverse gastrointestinal event is vomiting.

6. The tablet formulation of claim 1, wherein the adverse gastrointestinal event is diarrhea.

7. The tablet formulation of claim 1, wherein the amount of adagrasib in the tablet formulation is at least, or about, 200 mg.

8. The tablet formulation of claim 1, wherein the amount of adagrasib in the tablet formulation is at least, or about, 300 mg.

9. The tablet formulation of claim 1, wherein the amount of adagrasib in the tablet formulation is at least, or about, 400 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.